In 2004, the WHO classified atypical pituitary adenoma as a distinct adenoma subtype. However, the clinical significance of this distinction remains undetermined. The authors sought to define patient characteristics, tumor features, and treatment outcomes associated with atypical pituitary adenoma.
The authors reviewed records of patients who underwent resection of pituitary adenoma at the University of California, San Francisco, between 2007 and 2014. Per institutional protocol, adenomas exhibiting mitotic activity underwent evaluation for all 3 markers of atypicality (mitotic index, extensive p53 staining, and MIB-1 index ≥ 3%). Statistical analyses were performed using χ2, Fisher’s exact test, t-test, log-rank, and logistic regression.
Between 2007 and 2014, 701 patients underwent resection for pituitary adenoma. Among these patients, 122 adenomas exhibited mitotic activity and therefore were evaluated for all 3 markers of atypicality, with 36 tumors (5%) proving to be atypical. There were 21 female patients (58%) and 15 male patients (42%) in the atypical cohort, and 313 female patients (47%) and 352 male patients (53%) in the nonatypical cohort (p = 0.231). The mean age of patients in the atypical cohort was 37 years (range 10–65 years), which was significantly lower than the mean age of 49 years (range 10–93 years) for patients in the nonatypical cohort (p < 0.001). The most common presenting symptoms for patients with atypical adenomas were headaches (42%) and visual changes (33%). Atypical adenomas were more likely to be functional (78%) than nonatypical adenomas (42%; p < 0.001). Functional atypical adenomas were significantly larger than functional nonatypical adenomas (mean diameter 2.2 vs 1.4 cm; p = 0.009), as were nonfunctional atypical adenomas compared with nonfunctional nonatypical adenomas (mean diameter 3.3 vs 2.3 cm; p = 0.01). Among the entire adenoma cohort, larger presenting tumor size was associated with cavernous sinus invasion (p < 0.001), and subtotal resection was associated with cavernous sinus invasion (p < 0.001) and larger size (p < 0.001) on binomial multivariate regression. The median time until recurrence was 56 months for atypical adenomas, 129 months for functional nonatypical adenomas, and 204 months for nonfunctional nonatypical adenomas (p < 0.001). Functional atypical adenomas recurred more frequently and significantly earlier than functional nonatypical adenomas (p < 0.001). When accounting for extent of resection, cavernous sinus invasion, size, age, sex, and functional subtype, atypicality remained a significant predictor of earlier recurrence among functional adenomas (p = 0.002).
When compared with nonatypical pituitary adenomas, atypical adenomas are more likely to present in younger patients at a larger size, are more often hormonally hypersecretory, and are associated with earlier recurrence. These features lend credence to atypical pituitary adenomas being a distinct clinical entity in addition to a discrete pathological diagnosis.
ABBREVIATIONSADC = apparent diffusion coefficient; HPF = high-power field; UCSF = University of California, San Francisco.
Correspondence Martin J. Rutkowski, Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Ave., M-779, San Francisco, CA 94143. email: email@example.com.INCLUDE WHEN CITING Published online June 9, 2017; DOI: 10.3171/2016.12.JNS162126.
Dr. Rutkowski and Mr. Alward contributed equally to this work.
Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
BoxermanJLRoggJMDonahueJEMachanJTGoldmanMADobersteinCE: Preoperative MRI evaluation of pituitary macroadenoma: imaging features predictive of successful transsphenoidal surgery. AJR Am J Roentgenol195:720–7282010
ChiloiroS, DogliettoF, TrapassoB, IacovazzoD, GiampietroA, Di NardoF, : Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. 101:143–150, 201510.1159/00037544825633744)| false
Del Basso De CaroMSolariDPagliucaFVillaAGuadagnoECavalloLM: Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev40:105–1142017
Del Basso De CaroM, SolariD, PagliucaF, VillaA, GuadagnoE, CavalloLM, : Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. 40:105–114, 201710.1007/s10143-016-0740-9)| false
GejmanR, SwearingenB, Hedley-WhyteET: Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. 39:758–766, 200810.1016/j.humpath.2007.10.00418439942)| false
HentschelSJ, McCutcheonE, MooreW, DurityFA: P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. 30:215–219, 20031294594410.1017/S0317167100002614)| false
HoneggerJPrettinCFeuerhakeFPetrickMSchulte-MöntingJReinckeM: Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg99:674–6792003
Jaffrain-ReaMLDi StefanoDMinnitiGEspositoVBultriniAFerrettiE: A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer9:103–1132002
Jaffrain-ReaML, Di StefanoD, MinnitiG, EspositoV, BultriniA, FerrettiE, : A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. 9:103–113, 200210.1677/erc.0.0090103)| false
KimJS, LeeYS, JungMJ, HongYK: The predictive value of pathologic features in pituitary adenoma and correlation with pituitary adenoma recurrence. 50:419–425, 201610.4132/jptm.2016.06.3027713217)| false
KnospE, SteinerE, KitzK, MatulaC: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. 33:610–618, 19938232800)| false
LosaMBarzaghiRLMortiniPFranzinAMangiliFTerreniMR: Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro- and macroadenomas. Am J Pathol156:245–2512000
LosaM, BarzaghiRL, MortiniP, FranzinA, MangiliF, TerreniMR, : Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro- and macroadenomas. 156:245–251, 20001062367310.1016/S0002-9440(10)64725-6)| false
LosaMFranzinAMangiliFTerreniMRBarzaghiRVegliaF: Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery47:1313–13192000
LouisDNPerryAReifenbergerGvon DeimlingAFigarella-BrangerDCaveneeWK: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol131:803–8202016
LouisDN, PerryA, ReifenbergerG, von DeimlingA, Figarella-BrangerD, CaveneeWK, : The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. 131:803–820, 20162715793110.1007/s00401-016-1545-1)| false
MastronardiLGuiducciASperaCPuzzilliFLiberatiFMairaG: Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol52:107–1111999
MastronardiL, GuiducciA, SperaC, PuzzilliF, LiberatiF, MairaG: Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. 52:107–111, 199910.1136/jcp.52.2.10710396237)| false
MiermeisterCPPetersennSBuchfelderMFahlbuschRLüdeckeDKHölskenA: Histological criteria for atypical pituitary adenomas—data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun3:502015(Erratum in Acta Neuropathol Commun 4:21 2016)
SaegerWLüdeckeDKBuchfelderMFahlbuschRQuabbeHJPetersennS: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol156:203–2162007
SaegerW, LüdeckeDK, BuchfelderM, FahlbuschR, QuabbeHJ, PetersennS: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. 156:203–216, 200710.1530/eje.1.0232617287410)| false
ThaparKKovacsKScheithauerBWStefaneanuLHorvathEPerniconePJ: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery38:99–1071996
ThaparK, KovacsK, ScheithauerBW, StefaneanuL, HorvathE, PerniconePJ, : Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. 38:99–107, 1996874795710.1097/00006123-199601000-00024)| false
WierinckxA, AugerC, DevauchelleP, ReynaudA, ChevallierP, JanM, : A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. 14:887–900, 20071791411710.1677/ERC-07-0062)| false